IL283937A - Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer - Google Patents
Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancerInfo
- Publication number
- IL283937A IL283937A IL283937A IL28393721A IL283937A IL 283937 A IL283937 A IL 283937A IL 283937 A IL283937 A IL 283937A IL 28393721 A IL28393721 A IL 28393721A IL 283937 A IL283937 A IL 283937A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- cdk4
- cancer
- treatment
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782767P | 2018-12-20 | 2018-12-20 | |
| US201962793128P | 2019-01-16 | 2019-01-16 | |
| PCT/IB2019/060987 WO2020128878A1 (en) | 2018-12-20 | 2019-12-18 | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL283937A true IL283937A (en) | 2021-07-29 |
Family
ID=69165429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283937A IL283937A (en) | 2018-12-20 | 2021-06-13 | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3897591A1 (en) |
| JP (1) | JP2022514056A (en) |
| KR (1) | KR20210105388A (en) |
| CN (1) | CN113453671A (en) |
| AU (1) | AU2019407159A1 (en) |
| BR (1) | BR112021011699A2 (en) |
| CA (1) | CA3123510A1 (en) |
| CL (1) | CL2021001623A1 (en) |
| IL (1) | IL283937A (en) |
| MX (1) | MX2021007477A (en) |
| TW (1) | TW202038964A (en) |
| WO (1) | WO2020128878A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109715163B (en) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | Therapeutic combination comprising a RAF inhibitor and an ERK inhibitor |
| JP7309614B2 (en) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | combination therapy |
| US20240000789A1 (en) * | 2020-05-12 | 2024-01-04 | Novartis Ag | Therapeutic combinations comprising a craf inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091876A1 (en) * | 2012-07-26 | 2015-03-04 | Novartis Ag | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US20180250302A1 (en) * | 2015-08-28 | 2018-09-06 | Giordano Caponigro | Combination of ribociclib and dabrafenib for treating or preventing cancer |
| JP7309614B2 (en) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | combination therapy |
-
2019
- 2019-12-18 WO PCT/IB2019/060987 patent/WO2020128878A1/en unknown
- 2019-12-18 CA CA3123510A patent/CA3123510A1/en active Pending
- 2019-12-18 KR KR1020217022093A patent/KR20210105388A/en not_active Application Discontinuation
- 2019-12-18 MX MX2021007477A patent/MX2021007477A/en unknown
- 2019-12-18 CN CN201980092575.1A patent/CN113453671A/en active Pending
- 2019-12-18 BR BR112021011699-0A patent/BR112021011699A2/en not_active Application Discontinuation
- 2019-12-18 JP JP2021535501A patent/JP2022514056A/en active Pending
- 2019-12-18 AU AU2019407159A patent/AU2019407159A1/en not_active Abandoned
- 2019-12-18 EP EP19836553.8A patent/EP3897591A1/en not_active Withdrawn
- 2019-12-20 TW TW108147073A patent/TW202038964A/en unknown
-
2021
- 2021-06-13 IL IL283937A patent/IL283937A/en unknown
- 2021-06-17 CL CL2021001623A patent/CL2021001623A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113453671A (en) | 2021-09-28 |
| CL2021001623A1 (en) | 2022-02-11 |
| EP3897591A1 (en) | 2021-10-27 |
| AU2019407159A1 (en) | 2021-07-15 |
| TW202038964A (en) | 2020-11-01 |
| JP2022514056A (en) | 2022-02-09 |
| KR20210105388A (en) | 2021-08-26 |
| WO2020128878A1 (en) | 2020-06-25 |
| CA3123510A1 (en) | 2020-06-25 |
| MX2021007477A (en) | 2021-08-05 |
| BR112021011699A2 (en) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948A (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| IL283937A (en) | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer | |
| IL273031A (en) | Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine | |
| PT3860990T (en) | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | |
| IL266623A (en) | Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer | |
| IL289167A (en) | 2h-indazole derivatives and their use in the treatment of disease | |
| IL281495A (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| IL286334A (en) | Modified micrornas and their use in the treatment of cancer | |
| IL284053A (en) | Novel compounds and their use in therapy | |
| EP3897725A4 (en) | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer | |
| IL277805A (en) | Use of gaboxadol in the treatment of substance use disorders | |
| ZA201905402B (en) | Compounds and their use in the treatment of schistosomiasis | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL290192A (en) | Nitenin analogue compounds and their use in the treatment of chronic and acute pain | |
| IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| SG11202105276TA (en) | Oligo-benzamide analogs and their use in cancer treatment | |
| EP3697413A4 (en) | Combination therapy of fractionated radiation and sapc-dops for the treatment of tumors | |
| GB2581035B (en) | Novel compounds and their use in therapy | |
| HUP1900281A1 (en) | Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer | |
| EP4025304C0 (en) | Thioridazine derivatives and their use for the treatment of cancer | |
| GB201914640D0 (en) | Novel compounds and their use in therapy | |
| GB201913448D0 (en) | Novel compounds and their use in therapy | |
| GB201913450D0 (en) | Novel compounds and their use in therapy | |
| GB201909790D0 (en) | Novel compounds and their use in therapy |